Guerbet

Guerbet to Showcase its UNIK Solution at RSNA 2020

Retrieved on: 
Thursday, November 12, 2020
Radiological Society of North America, RSNA, Guerbet, Unik, Unik, Health care

PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ --Guerbet (GBT) a global leader in medical imaging, announced today that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America (RSNA).

Key Points: 
  • PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ --Guerbet (GBT) a global leader in medical imaging, announced today that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America (RSNA).
  • UNIK is a flexible solution designed to create value by reflecting healthcare professionals' specific needs and improvement areas.
  • By understanding customers' internal processes, Guerbet can provide an ecosystem of value by interconnecting its comprehensive portfolio of contrast media, injection solutions, digital solutions and technical support.
  • Key benefits of UNIK include:
    "We look forward to virtually engaging RSNA participants and sharing how our product portfolio, led by UNIK, provides benefits for healthcare providers and their patients," said Thomas McLaughlin, VP, Guerbet North America.

Guerbet Optimizes its Industrial Network / Sale of the Montreal pharmaceutical site

Retrieved on: 
Wednesday, July 15, 2020
Guerbet, Syringe, Technology, Health

Villepinte (France), July 15, 2020 - 18:00 CET - Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes.

Key Points: 
  • Villepinte (France), July 15, 2020 - 18:00 CET - Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes.
  • Guerbet will gradually transfer its contrast agent production, carried out previously in Montreal, to its pharmaceutical sites in France and the USA.
  • Guerbet sells this site as part of its plans to optimize its industrial network.
  • Thanks to this sale we can optimize capacity utilization at our three pharmaceutical sites, which produce products for Guerbet alone.

Sasol Announces Beneficial Operations of Fifth and Sixth Lake Charles Chemicals Project Facilities

Retrieved on: 
Tuesday, June 23, 2020
Chemistry, Physical sciences, Sasol, Guerbet, Lake Charles, Companies

HOUSTON, June 23, 2020 /PRNewswire/ -- Sasol today announced that the Guerbet alcohol unit at our Lake Charles Chemicals Project (LCCP) achieved beneficial operations on 19 June 2020.

Key Points: 
  • HOUSTON, June 23, 2020 /PRNewswire/ -- Sasol today announced that the Guerbet alcohol unit at our Lake Charles Chemicals Project (LCCP) achieved beneficial operations on 19 June 2020.
  • The beneficial operations of these LCCP facilities progresses Sasol's seven-unit U.S. Gulf Coast mega project to the cusp of completion," said Sasol President and Chief Executive Officer, Fleetwood Grobler.
  • Sasol is a recognised leader in chemicals for essential care markets such as laundry, home care, personal care and hygiene.
  • The project and operations teams from both Lake Charles and Brunsbuettel worked exceedingly well to bring the Guerbet unit onstream without problems.

Sasol Announces Beneficial Operations of Fifth and Sixth Lake Charles Chemicals Project Facilities

Retrieved on: 
Tuesday, June 23, 2020
Chemistry, Physical sciences, Sasol, Guerbet, Lake Charles, Companies

HOUSTON, June 23, 2020 /PRNewswire/ -- Sasol today announced that the Guerbet alcohol unit at our Lake Charles Chemicals Project (LCCP) achieved beneficial operations on 19 June 2020.

Key Points: 
  • HOUSTON, June 23, 2020 /PRNewswire/ -- Sasol today announced that the Guerbet alcohol unit at our Lake Charles Chemicals Project (LCCP) achieved beneficial operations on 19 June 2020.
  • The beneficial operations of these LCCP facilities progresses Sasol's seven-unit U.S. Gulf Coast mega project to the cusp of completion," said Sasol President and Chief Executive Officer, Fleetwood Grobler.
  • Sasol is a recognised leader in chemicals for essential care markets such as laundry, home care, personal care and hygiene.
  • The project and operations teams from both Lake Charles and Brunsbuettel worked exceedingly well to bring the Guerbet unit onstream without problems.

Guerbet: 1st quarter 2020 revenue

Retrieved on: 
Thursday, April 23, 2020
Euronext, Guerbet

Revenue in the Americas reached 70.6million, up 4.6% (+6.4% at constant exchange rates) thanks to greater volumes and despite limited price erosion.

Key Points: 
  • Revenue in the Americas reached 70.6million, up 4.6% (+6.4% at constant exchange rates) thanks to greater volumes and despite limited price erosion.
  • - CT/CathLab2 revenue grew 2.3% to 107million (+3.5% at constant exchange rates) thanks to the good level of sales of Xenetix with stable sales of Optiray.
  • However, despite this unprecedented situation in health and business, Guerbet expects sales to recover during the 2nd quarter as the lockdown is gradually lifted.
  • Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 817million in revenue in 2019.

Guerbet: 2019 annual results

Retrieved on: 
Tuesday, March 24, 2020
Mortgage, Personal finance, Cash flow, Refinancing, Euronext, Free cash flow, Guerbet, Economy, Business, Articles

The Group indicates that the phaseIII costs incurred in 2019 totalled approximately 7million.

Key Points: 
  • The Group indicates that the phaseIII costs incurred in 2019 totalled approximately 7million.
  • Free cash flow was up significantly in 2019, resulting especially from the Groups inventory reduction initiatives and leading to a decrease in net debt of approximately 28million for the 2019 financial year (excluding IFRS16 impact).
  • As a reminder, Guerbet signed a five-year 500million credit agreement on 13 February 2019 to refinance its existing debt.
  • Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 817 million in revenue in 2019.

Guerbet To Showcase Next Generation Digital Solutions at HIMSS20

Retrieved on: 
Wednesday, February 26, 2020
Medicine, Guerbet, Health, Medical imaging, Medical diagnosis, Branches of biology

Guerbet has partnered with InterSystems, a global leader in information technology platforms, to optimize the integration of Contrast&Care into IT systems of hospitals and medical imaging centers worldwide.

Key Points: 
  • Guerbet has partnered with InterSystems, a global leader in information technology platforms, to optimize the integration of Contrast&Care into IT systems of hospitals and medical imaging centers worldwide.
  • To learn how Guerbet is helping providers close the loop with smart connectivity, visit Guerbet at booth #4488, InterSystems booth #3301, or visit www.digitalsolutions.guerbet.us .
  • Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients.
  • Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 817 million in revenue in 2019.

Guerbet: 2019 Revenue

Retrieved on: 
Thursday, February 13, 2020
Euronext, Guerbet, Exchange rate, Economy

The analysis of activity over the 2019 financial year shows that:

Key Points: 
  • The analysis of activity over the 2019 financial year shows that:
    Diagnostic Imaging sales grew to 711.0 million at constant exchange rates (+3.0%) and 719.5 million at current exchange rates.
  • In 2019, activity suffered from the planned withdrawal of Optimark from the market.
  • It showed revenue at constant exchange rates of 73.5 million, up 12.5% (75.5 million at current exchange rates).
  • Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 817 million in revenue in 2019.

Guerbet Announces Appointment of Thomas McLaughlin as Vice President for North America

Retrieved on: 
Wednesday, January 8, 2020
Guerbet, McLaughlin, Surnames, Surname, Names

PRINCETON, N.J., Jan. 8, 2020 /PRNewswire/ -- Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that Thomas McLaughlin has been appointed Vice President, North America.

Key Points: 
  • PRINCETON, N.J., Jan. 8, 2020 /PRNewswire/ -- Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that Thomas McLaughlin has been appointed Vice President, North America.
  • In this role, McLaughlin will oversee and ensure the growth of Guerbet diagnostic and interventional solutions together with the digital and AI portfolio.
  • McLaughlintakes on the Vice President role after serving as Guerbet's General Manager of North American Sales and Service, where he led the company's North American sales group to consecutive year-over-year growth.
  • "We are delighted that Tom McLaughlin will lead Guerbet's North America Executive team," said David Hale, Guerbet Chief Executive Officer.

Global Contrast Media/Contrast Agents Market Outlook 2019-2024 - Opportunities Presented by Generic Contrast Media & Increasing Research

Retrieved on: 
Wednesday, December 18, 2019
Companies, Industries, Medicine, Medical physics, Medical equipment, IG Farben, Bracco, Radiology, GE Healthcare, Guerbet, Port, Bayer

GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany),Guerbet (France), Lantheus (US) were the leading players in the contrast media market.

Key Points: 
  • GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany),Guerbet (France), Lantheus (US) were the leading players in the contrast media market.
  • The contrast media market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide.
  • The growing number of research & funding activities for contrast agents and their applications provide immense opportunities for players in the contrast media market.
  • In 2019, X-ray/CT procedures segment is expected to command the largest share of the global contrast media market.